Usefulness of hydrocortisone prophylaxis for oxaliplatin-induced hypersensitivity reactions: A retrospective study
- 8 September 2025
- journal article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Abstract
Introduction: Oxaliplatin is a platinum-based drug widely used for treating colorectal cancer. However, its use is often complicated by hypersensitivity reactions and other adverse effects, including peripheral neuropathy and myelosuppression. We evaluated the efficacy of prophylactic hydrocortisone administration in preventing hypersensitivity reactions during oxaliplatin therapy in patients with colorectal cancer. Methods: Patients who received oxaliplatin between January 2017 and December 2023 were retrospectively analyzed. Among them, 53 received 100 mg of hydrocortisone as a preventive measure when the cumulative oxaliplatin dose exceeded 400 mg/m 2 or if they experienced a treatment interruption of >8 weeks. We compared the incidence and severity of hypersensitivity reactions, as well as cumulative oxaliplatin dose, between patients who received routine premedication only (the Routine group) and those who received additional hydrocortisone prophylaxis (the Prophylaxis group). Results: Overall, 370 patients were included in the study. Hypersensitivity reactions occurred in 23 patients (18 in the Routine group and 5 in the Prophylaxis group), with a significantly higher cumulative dose of oxaliplatin in the Prophylaxis group (644 vs. 1383 mg/m 2 , p = 0.0032). Severe reactions were observed only in the Routine group. Treatment discontinuation owing to hypersensitivity reactions was more common in the Routine group (five patients) than in the Prophylaxis group (one patient). Conclusions: Prophylactic administration of hydrocortisone may promote oxaliplatin treatment continuation. This approach is proposed as a potential strategy for preventing oxaliplatin-induced hypersensitivity reactions.Keywords
This publication has 18 references indexed in Scilit:
- The effect of different types of oral or intravenous corticosteroids on capillary blood glucose levels in hospitalized inpatients with and without diabetesClinical Therapeutics, 2023
- Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature ReviewClinical Reviews in Allergy & Immunology, 2022
- Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patientsInternational Journal of Clinical Oncology, 2021
- Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter AnalysisCurrent Medical Science, 2021
- Hypersensitivity Reactions to Platinum Agents and TaxanesClinical Reviews in Allergy & Immunology, 2021
- Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancerCancer Chemotherapy and Pharmacology, 2017
- Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposureCancer Chemotherapy and Pharmacology, 2014
- High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatinInternational Journal of Clinical Oncology, 2011
- Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapyBritish Journal of Cancer, 2006
- Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancerAnnals of Oncology, 2000